Search Results

1 - 3 of 3 items :

  • Pentoxifylline x
  • Internal Medicine, other x
Clear All
Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial

therapeutic interventions to control concomitant disease, for example, hyperlipidemia, hypertension and type 2 DM. Pentoxifylline (PTX) is known to decrease oxidative stress.[ 10 ] PTX also has hydroxyl and peroxyl radical scavenging effects[ 11 ] and specifically inhibits lipid peroxidation.[ 12 ] Moreover, pentoxifylline has anti-inflammatory properties and it is also known to definitely suppress TNF- α gene transcription, preventing TNF- α synthesis.[ 13 ] Therefore, PTX plays an important role in the inhibition of second hit hypothesis required for pathogenesis of

Open access
Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient

management of NASH. [ 22 ] Among different drugs tested, [ 23 ] vitamin E, [ 24 , 25 ] pioglitazone, [ 25 ] liraglutide, [ 26 ] telmisartan, [ 27 ] pentoxifylline [ 28 ] were found to improve histological activity and fibrosis in different degrees. But these must be balanced with their potential adverse effects. Therefore, diet and lifestyle modification, with weight reduction remains the mainstay of treatment in these patients. [ 16 , 22 ] Previous studies testing the effectiveness of lifestyle modification in NAFLD have found that 7 to 10% weight loss is

Open access
Pharmacological Approaches for Nonalcoholic Fatty Liver Disease

disease. Atherosclerosis 239: 192-202, 2015. 28. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 19: 6911-6918, 2013. 29. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J 91: 92–101, 2015. 30. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 10: 49, 2011

Open access